Share the post "Orchid Pharma : Q4 2024 Financial Quarterly Report : YoY Sales Up 3.43 %, QoQ Down 1.58 %"
Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 3.43 % in the past year, decrease in net sales/revenue by -1.58 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 353.36 %. Marginal increase in other income during this quarter, up by 87.15%.
- Profit over the Year and quarter: Challenges in sustaining profitability for Orchid Pharma Limited. Profit dropped by -44.27 % Year to Year, Orchid Pharma Limited’s profitability increased by 11.98 % in this quarter.
- EPS over the Year and quarter: EPS declined by -53.00 % Year to Year. EPS increased by 10.19 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 209.901 Cr | Rs. 220.591 Cr | Rs. 217.102 Cr | -1.58 % | + 3.43 % |
| Expenses | Rs. 170.22 Cr | Rs. 185.21 Cr | Rs. 188.19 Cr | + 1.61 % | + 10.56 % |
| Operating Profit | Rs. 39.68 Cr | Rs. 35.38 Cr | Rs. 28.91 Cr | -18.29 % | -27.14 % |
| OPM % | 18.9 % | 16.04 % | 13.32 % | -2.72 % | -5.58 % |
| Other Income | Rs. -5.06 Cr | Rs. 6.85 Cr | Rs. 12.82 Cr | + 87.15 % | + 353.36 % |
| Interest | Rs. 7.48 Cr | Rs. 3.54 Cr | Rs. 3.47 Cr | -1.98 % | -53.61 % |
| Depreciation | Rs. 7.21 Cr | Rs. 9.27 Cr | Rs. 8.42 Cr | -9.17 % | + 16.78 % |
| Profit before tax | Rs. 19.93 Cr | Rs. 29.42 Cr | Rs. 29.84 Cr | + 1.43 % | + 49.72 % |
| Tax % | 0 % | 0 % | 10.27 % | + 10.27 % | + 10.27 % |
| Net Profit | Rs. 59.14 Cr | Rs. 29.43 Cr | Rs. 32.96 Cr | + 11.99 % | -44.27 % |
| EPS in Rs | Rs. 14.49 | Rs. 6.18 | Rs. 6.81 | + 10.19 % | -53 % |
Today, we’re looking at Orchid Pharma Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 3.43 %. However, it did see a marginal slip of -1.58 % from the previous quarter. Expenses ticked up slightly by 1.61 % quarter-on-quarter, aligning with the annual rise of 10.56 %. Operating profit, while down -27.14 % compared to last year, faced a quarter-on-quarter dip of -18.29 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -5.58 %, but a shrinkage of -2.72 % sequentially. Other income rose by 87.15 % compared to the last quarter, despite an annual growth of 353.36 %. Interest expenses dropped significantly by -1.98 % from the previous quarter, yet the year-over-year decrease remains at a moderate -53.61 %. Depreciation costs fell by -9.17 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 16.78 %. Profit before tax grew annually by 49.72 % but saw an increase from the preceding quarter by 1.43 %.
Tax expenses as a percentage of profits increased slightly by 10.27 % compared to last year, with a more notable quarter-on-quarter increase of 10.27 %. Net profit fell by -44.27 % year-on-year but experienced a 11.99 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -53 % but a quarterly rise of 10.19 %. In summary, Orchid Pharma Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 209.901 Cr | Rs. 220.591 Cr | Rs. 217.102 Cr | -1.58 % | + 3.43 % |
| Expenses | Rs. 170.22 Cr | Rs. 185.21 Cr | Rs. 188.19 Cr | + 1.61 % | + 10.56 % |
| Operating Profit | Rs. 39.68 Cr | Rs. 35.38 Cr | Rs. 28.91 Cr | -18.29 % | -27.14 % |
| Net Profit | Rs. 59.14 Cr | Rs. 29.43 Cr | Rs. 32.96 Cr | + 11.99 % | -44.27 % |
| EPS in Rs | Rs. 14.49 | Rs. 6.18 | Rs. 6.81 | + 10.19 % | -53 % |
In reviewing Orchid Pharma Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 3.43 % year-on-year growth, although there was a slight dip of -1.58 % from the previous quarter. Expenses rose by 10.56 % compared to the previous year, with a 1.61 % increase quarter-on-quarter. Operating Profit dropped by -27.14 % annually, and saw a -18.29 % decrease from the last quarter.
Net Profit showed yearly decrease of -44.27 %, and experienced a 11.99 % increase from the previous quarter. Earnings Per Share (EPS) fell by -53 % annually, however rose by 10.19 % compared to the last quarter. In essence, while Orchid Pharma Limited faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
